All In Biotech

Drug Trial Radar · NCT07500207

A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

A Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Lyophilized Human Rabies Vaccine (Human Diploid Cell) Administered Via Different Immunization Schedules Using a Randomized, Blinded, Positive-Controlled Design

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

3,000

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

May 25, 2026

Study completion Mar 25, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group

Conditions

  • Rabies Prevention

Interventions

  • Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell)Biological

    Dosage schedule: Five-dose regimen: one dose on days 0, 3, 7, 14, and 28 respectively; 2-1-1 regimen: administration on days 0, 7, and 21, with 2 doses on day 0 and 1 dose on each of the other days; Simplified four-dose regimen: one dose on days 0, 3, 7, and 14, or one dose on days 0, 3, 7, and 28 respectively.

  • approved Rabies vaccineBiological

    One dose shall be administered on days 0, 3, 7, 14, and 28 respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. neutralizing antibodies after the first doseTime frame: 14 days and 42 day after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • sichuan CDC

    Neijiang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.